J. Moore
4 Papers
2 Citations
J. Moore is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 4 publications.
Chat about Author
Papers
Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis
Xavier Brennan,Barbara Withers,Andrew Jabbour,Sam Milliken,Eugene Kotlyar,Keith Fay,David D.F. Ma,Kavitha Muthiah,Nada Hamad,Anthony J. Dodds,Nicole Karina Bart,Anne Keogh,Christopher S. Hayward,Peter S. Macdonald,J. Moore +14 more
TL;DR: A retrospective analysis comparing the traditional melphalan and dexamethasone protocol with cyclophosphamide, bortezomib and DexamethAsone in late‐stage cardiac AL amyloidosis found both regimens provided meaningful responses in this difficult to treat patient group.
3
P90: lanadelumab efficacy and safety regardless of baseline attack rate in patients with previous long‐term prophylaxis of hereditary angioedema: a post hoc subanalysis of help ole
T. Gray,Sean Riminton,Andrew Carr,Elissa K. Deenick,Tri T. Phan,Anthony D. Kelleher,Winnie Tong,J. Moore,Louise,Evans,Catherine Toong,Ari Murad,A. Kane,Hilary Longhurst,Aleena Banerji,H Q Ren,Elisabeth Smith,Zia Choudhry +17 more
TL;DR: A 36-year-old male with a history of residence in Africa, presented with subacute onset of progressive obstructive urinary symptoms and bilateral flank pain in the absence of constitutional symptoms and reported abnormally increased metabolism in the right kidney, abdominal lymph nodes, body of pancreas and most markedly, the prostate gland.
Rates of Menstrual History-Taking and Counseling With Anticancer Treatments Are Low: People Who Menstruate Deserve Gender-Specific Cancer Care.
Verity L. Chadwick,G. Mills,Catherine Tang,Antoinette Anazodo,Rachel F Dear,R. Rodgers,Orly Lavee,Sam Milliken,Georgia McCaughan,J. Moore,Barbara Withers,Nada Hamad +11 more
TL;DR: Menstrual care should be integral to cancer care for people who menstruate, and higher engagement could be achieved through education of medical and allied health staff, information technology systems automating prompts and referral pathways, regular audits to ensure compliance, better alliances between cancer and fertility specialists, and the creation of accessible patient information to promote awareness and facilitate discussion as discussed by the authors.
Targeting the BRAF pathway in haematological diseases
Matthew J Rees,Michael Dickinson,J. S. Paterson,Andrew Grigg,J. Moore,Piers Blombery,John F. Seymour +6 more
TL;DR: In this paper , the authors review the Australian experience of BRAF/MEK inhibitor therapy in rare haematological cancers, including hairy cell leukaemia, Erdheim-Chester disease and Langerhans cell histiocytosis.